Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Vivo Capital
AddedFeb 13, 2024
UpdatedJul 16, 2026
Vivo Capital

Vivo Capital

Operating

Vivo Capital LLC: A healthcare-focused investment firm operating in the US and China.

Location
Palo Alto, CA, US
Founded
1996
Firm
Compare
Portfolio
Employees
Website

Investments

SonoThera
SonoThera
Series B

Total Raised

$185.8M

Rounds

2

Series B$125MJune 2026
Silence Therapeutics
Silence Therapeutics
Public

Total Raised

$248.7M

Rounds

6

Post Ipo Equity$120MFebruary 2024
Adarx Pharmaceuticals
Adarx Pharmaceuticals

Total Raised

$332M

Rounds

5

Series C$200MAugust 2023
Ossium Health
Ossium Health

Total Raised

$128.9M

Rounds

6

Series C$52MJuly 2023
EpiBiologics
EpiBiologics

Total Raised

$73M

Rounds

2

Series A$23MJuly 2023
Series A$50MMarch 2023
Delcath Systems
Delcath Systems
Public

Total Raised

$269.6M

Rounds

13

Post Ipo Equity$85MMarch 2023
Unicycive Therapeutics
Unicycive Therapeutics
Public

Total Raised

$36.6M

Rounds

4

Post Ipo Equity$30MMarch 2023
Rgenta Therapeutics
Rgenta Therapeutics

Total Raised

$116.9M

Rounds

6

Series A$52MNovember 2022
Seed$18MMay 2021
Bonum Therapeutics
Bonum Therapeutics

Total Raised

$93M

Rounds

1

Series A$93MNovember 2022
Neocis
Neocis

Total Raised

$183.1M

Rounds

9

Series D$40MOctober 2022
Inspirna
Inspirna

Total Raised

$144.6M

Rounds

6

Series D$55.1MJuly 2022
Tebra
Tebra

Total Raised

$137M

Rounds

3

Series B$72MJuly 2022
Cerebral Therapeutics
Cerebral Therapeutics

Total Raised

$85.8M

Rounds

4

Series C$40MJune 2022
Ocelot Bio
Ocelot Bio

Total Raised

$39M

Rounds

2

Series A$36MMarch 2022
HistoWiz
HistoWiz

Total Raised

$36.8M

Rounds

6

Series A$32.3MOctober 2021
Inbrace
Inbrace

Total Raised

$217.6M

Rounds

7

Series D$102MSeptember 2021
Attralus
Attralus

Total Raised

$141.2M

Rounds

3

Series B$116MSeptember 2021
Whitehawk Therapeutics
Whitehawk Therapeutics
Public

Total Raised

$250.5M

Rounds

4

Post Ipo Equity$155MAugust 2021
Neurogastrx
Neurogastrx

Total Raised

$105M

Rounds

2

Series B$60MAugust 2021
Scientia Vascular
Scientia Vascular

Total Raised

$80M

Rounds

3

Private Equity$50MMay 2021
Aerobiotix
Aerobiotix

Total Raised

$35M

Rounds

2

Series Unknown$25MMay 2021
Sera Prognostics
Sera Prognostics
Public

Total Raised

$245.6M

Rounds

12

Series E$100MApril 2021
Immune-Onc Therapeutics
Immune-Onc Therapeutics
Public

Total Raised

$140.1M

Rounds

6

Series B$73MMarch 2021